Kura Oncology, Inc. (NASDAQ:KURA) SVP Sells $38,948.63 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $7.77 on Wednesday. Kura Oncology, Inc. has a 1 year low of $6.98 and a 1 year high of $24.17. The stock has a market capitalization of $604.20 million, a P/E ratio of -3.29 and a beta of 0.81. The company’s 50-day moving average is $9.23 and its 200 day moving average is $15.69. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.01. During the same period in the previous year, the company posted ($0.50) EPS. On average, sell-side analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on KURA. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday, November 19th. Scotiabank decreased their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. UBS Group began coverage on Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Finally, Jefferies Financial Group dropped their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus target price of $27.38.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently added to or reduced their stakes in KURA. Harbor Capital Advisors Inc. increased its stake in shares of Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after acquiring an additional 2,076 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Kura Oncology by 251.5% in the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after purchasing an additional 58,422 shares in the last quarter. Quarry LP purchased a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $196,000. Finally, The Manufacturers Life Insurance Company increased its position in Kura Oncology by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.